Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527325 · ClinicalTrials.gov registry record · Phase 2
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
A Phase 2 study, sponsored by University of California, Irvine.
- Not yet
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT07527325 is a Phase 2 study that has not yet begun recruiting, run by University of California, Irvine. The registered enrollment target is 35 participants.
The verdict
NCT07527325, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Irvine.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Interventions
- DRUG Cemiplimab
- DRUG Fianlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07527325
The ClinicalTrials.gov registry entry for NCT07527325 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cemiplimab is the first listed.
NCT07527325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07527325 about?
NCT07527325 is a clinical study titled "Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma". This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
What is the current status of trial NCT07527325?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2026-07-01. Estimated completion is 2030-02-01.
What interventions are being tested in trial NCT07527325?
The interventions under investigation include: Cemiplimab (DRUG), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT07527325?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.